Recurrence rate of breast cancer and hormone preparations subcutaneous (goserelin) can be reduced

Breast cancer has become the first women in the top ten cancer, an average of 19 people with breast cancer. Traditional pre-menopausal breast cancer patients will be given after tamoxifen anti-hormone therapy to reduce breast cancer recurrence rate. The latest study found that if the patients without the use of tamoxifen, such as the phenomenon of hot flashes that the poor efficacy of the proposed formulations with subcutaneous hormone (goserelin), in order to increase the rate of breast cancer control, to avoid tumor recurrence. 

 National Cheng Kung University breast surgeon Dr. Tsai-Wang pointed out that in the treatment of breast cancer, the anti-hormone therapy of estrogen receptor-positive is very important in patients with postoperative adjuvant therapy. For pre-menopausal breast cancer patients, the medical community over the years has been the use of tamoxifen as a major anti-hormone therapy drugs, the delay for patients with early breast cancer recurrence and metastasis of breast cancer the opportunity; for advanced disease and metastasis of breast cancer suffering can be achieved to reduce the deterioration of the tumor and alleviate the effects of breast cancer for many years with proven experience in the use of a percent lower mortality rate. 

 Dr. Tsai-Wang pointed out that although the efficacy of tamoxifen has its own, but many patients with a long time because of their hot flashes caused much distress and other side effects, some people even want to stop there. However, according to at American Society of Clinical Oncology December and well-known in the Lancet journal published research has shown that taking tamoxifen have hot flashes phenomenon that drugs be effective, and this has become the treatment of breast cancer important drug reference. 

 Choi Chang-wang said that the medical community understand the indicators, the use of tamoxifen for the poor efficacy of the proposed merger of subcutaneous hormone preparations at the same time (goserelin) use, facilities play a month, allowing dormant ovaries, patients with lower hormone concentration, help control the tumor cells. According to clinical trials confirmed that agents with subcutaneous hormone (goserelin) can reduce the recurrence rate of one percent. The most important thing is, once about two years after the end of treatment, ovarian function can return to normal. 

 Choi Chang-wang said that the breast cancer three years and seven years after the peak period of recurrence of breast cancer, it is proposed to be immediately after the use of anti-hormone therapy to strengthen the control, to avoid the recurrence of breast cancer; At the same time, studies have found that the use of tamoxifen are hot flashes response of the human body is more related enzyme activation, the current medical community has been a key gene can be detected CYD2D6, if the enzyme does not belong to the early activation of those agents with subcutaneous hormone (goserelin), in order to grasp the timing of optimal treatment. 

 In addition, there is thrombosis due to tamoxifen, endometrial thickening, fatty liver, such as side effects, so for endometrial cancer, the risk of thrombosis and abnormal liver function can also use the subcutaneous hormonal agents (goserelin) in lieu of tamoxifen treatment.